Drug Pricing Fraud: When Manufacturer-Reported Numbers Change Government Payments

Drug pricing fraud uses knowingly false price reports to increase government payments or reduce the rebates a manufacturer owes. The discount is in the contract. The payment is in the ledger. The quarterly report leaves it out, assigns it to another product or treats it as something else. If you work in government pricing, contracting or finance, you may know exactly where the calculation parted company with the transaction.

Manufacturers supply the numbers behind Medicaid rebates, Medicare Part B reimbursement, federal purchasing limits and 340B ceiling prices. The commercial bargain and the government report can describe the same drug very differently. The person who understands the difference may be the person who can explain the case.

Government Payment Systems Use Manufacturer-Reported Numbers

Each program uses its own price input, with its own treatment of buyers, discounts and fees. The same concession can affect several calculations, but it does not belong in all of them on the same terms.

A low reported Average Manufacturer Price can shrink the rebate a manufacturer pays. A high reported Average Sales Price can increase what Medicare pays a health care provider. The direction matters as much as the discrepancy.

Wholesale acquisition cost is the manufacturer’s list price before discounts. Average wholesale price is a commercially published benchmark used in reimbursement arrangements. Marketing the spread means selling a drug on the profit a buyer can keep between its acquisition cost and the reimbursement benchmark. Historical average wholesale price cases turned that gap into a sales pitch.

At the pharmacy counter, usual-and-customary price reporting asks another question. The whistleblower in the Kmart complaint alleged that the pharmacy reported a higher price to government insurers than the cash price it offered customers.

How a Reported Number Becomes a Government Payment

The pricing calculation determines which commercial transactions reach the government. A hospital discount, a wholesaler payment or a product classification can change the result before the rebate invoice or reimbursement claim exists.

Medicaid AMP and Best Price

Average Manufacturer Price measures prices paid to the manufacturer by wholesalers supplying retail community pharmacies and by those pharmacies buying directly. Best Price captures the lowest qualifying price available to specified purchasers during the rebate period. The buyer, the product and the terms of the concession determine which transactions count.

For most branded drugs, the basic Medicaid rebate is the greater of 23.1% of Average Manufacturer Price or that price minus Best Price. Generic drugs use a basic rebate of 13% of Average Manufacturer Price. Both also have an inflation component. The cap that limited total rebates to Average Manufacturer Price ended in January 2024.

The customer classification matters too. Prices to 340B covered entities and Federal Supply Schedule purchasers are excluded from Best Price. Prices negotiated by Part D plans are also excluded. Which customer received the concession can determine whether the transaction reaches the calculation.

Best Price includes qualifying cash discounts, volume discounts, rebates and free goods contingent on a purchase. Bundled discounts must be allocated across the drugs or products in the arrangement. A discount can disappear from the reported price even while the customer receives every dollar of it.

Wyeth’s Protonix business shows why that matters. According to the government, Wyeth bundled discounts on Protonix Oral and Protonix IV to win hospital use. Patients discharged on the oral drug were likely to keep taking it, with Medicaid and other payers then paying nearly full price. The hospital discount bought access to the later prescription business.

Wyeth and Pfizer agreed to a $784.6 million settlement in 2016 over allegations that Wyeth concealed those bundled discounts and avoided hundreds of millions of dollars in Medicaid rebates. Two whistleblowers brought the allegations. The alleged bargain gave hospitals the discount while withholding the corresponding rebate from state programs that pay for Medicaid patients’ care.

Drug Classification Changes the Rebate

The drug category reported to Medicaid changes the rebate calculation. A pricing analyst’s classification field can therefore carry the financial consequence of a much more visible commercial decision.

Mylan settled EpiPen rebate allegations for $465 million in 2017. The government alleged that Mylan reported EpiPen as a generic despite the absence of a therapeutically equivalent drug. From 2010 through 2016, that treatment let the company avoid the brand-drug inflation rebates while sharply increasing its private-market price.

A rival drugmaker, Sanofi-Aventis US LLC, brought the case over the category Mylan reported to Medicaid. Generic drugs have had their own inflation rebate since 2017.

The Base Date Can Erase Earlier Price Increases

A drug’s base-date Average Manufacturer Price anchors the Medicaid inflation rebate. Moving that baseline forward can remove earlier price increases from the calculation.

In the Acthar rebate settlement announced in 2022, the government alleged that Mallinckrodt and its predecessor, Questcor, calculated rebates as though Acthar were first marketed in 2013. Mallinckrodt admitted that the drug was approved and marketed before 1990 and agreed to correct its base-date Average Manufacturer Price.

The government said the Centers for Medicare & Medicaid Services had repeatedly warned Mallinckrodt that it could not ignore the earlier price increases. That connects the calculation to knowledge inside the company. The relevant history sits in the product records, the baseline used for rebates and the response to the warnings.

Medicare Part B ASP and Unreported Concessions

Average Sales Price measures qualifying manufacturer sales divided by units sold, after the required price concessions. Medicare Part B typically uses a payment rate of 106% of ASP. Leaving a concession out can keep the reimbursement benchmark above the price the customer effectively paid.

Regeneron illustrates a concession that travels through someone else’s bill. In its April 2024 complaint announcement, the Justice Department alleged that Regeneron paid credit-card processing fees for physicians buying Eylea without reporting those payments as Average Sales Price concessions. Physicians could use their cards, retain the lower cash price and receive card benefits while Regeneron absorbed the transaction cost.

A whistleblower complaint describes the related distributor-discount allegation:

The alleged concealment depended on whose discount appeared in the records. A manufacturer payment to the distributor could benefit the physician while the manufacturer’s report left that benefit out. The distributor agreement and the customer transaction tell the rest of the price story.

Federal Supply Schedule and Non-FAMP

Federal purchasing uses non-Federal Average Manufacturer Price to calculate the Federal Ceiling Price. For covered drugs, the ceiling starts at 76% of non-FAMP, with an additional inflation discount. It applies to the Department of Veterans Affairs, Department of Defense, Public Health Service and Coast Guard.

Manufacturers report non-Federal Average Manufacturer Price quarterly and must make covered drugs available through the Federal Supply Schedule. Calculation errors, missing covered products and failures to honor contractual price reductions can each leave federal purchasers paying too much.

Sanofi Pasteur settled federal drug overcharge allegations in 2017 after disclosing incorrect ceiling-price calculations. Its disclosure covered 2007 through 2011. The Department of Veterans Affairs inspector general found that the overcharges reached back to 2002.

A Hidden Discount Can Raise the 340B Ceiling

A concealed Best Price discount can leave a safety-net healthcare purchaser paying too much for a drug. The 340B ceiling equals the preceding quarter’s Average Manufacturer Price minus the Medicaid unit rebate amount. Hiding a qualifying discount can shrink that rebate and raise the ceiling.

Aventis settled allegations about private-label discounts in 2009. The government alleged that the company repackaged nasal sprays under a different label for Kaiser Permanente and kept those lower prices out of Best Price. The settlement included over $6 million for Public Health Service entities that had paid inflated prices.

The alleged reporting choice affected both programs: Medicaid lost rebates and safety-net purchasers paid inflated prices.

The Same Payment Can Be a Discount or a Service Fee

Calling a payment a service fee changes whether it reduces the reported drug price. The underlying service and who receives the benefit determine whether that treatment fits.

A bona fide service fee must reflect fair market value for an itemized service actually performed for the manufacturer, something the manufacturer would otherwise do or buy. The recipient must not pass the fee on to a customer. The agreement, the service delivered, the valuation and any benefit passed downstream all matter.

In the Medicaid Average Manufacturer Price cases, the alleged error went toward a smaller reported price. AstraZeneca and Cephalon settled allegations in 2015 that they improperly deducted wholesaler service fees from Average Manufacturer Price, reducing rebates owed to states. The case was brought by a pharmacist.

In the Part B allegation against Regeneron, the direction reversed. The government alleged that Regeneron called customer benefits bona fide service fees and omitted them from price concessions, leaving Average Sales Price too high. One treatment shrinks the manufacturer’s rebate bill. The other enlarges Medicare’s reimbursement bill.

Bristol-Myers Squibb settled Medicaid rebate allegations in 2021 over alleged Average Manufacturer Price underreporting involving both wholesaler service fees and price-appreciation payments. When a manufacturer raises its price, a wholesaler can gain value on inventory it already holds. A contract can return part of that gain to the manufacturer. The government alleged that Bristol-Myers Squibb excluded that additional value from Average Manufacturer Price. The inventory provision belonged beside the sales invoice in the rebate calculation.

The wider economics explain why an invoice alone leaves so much out. The USC Schaeffer Center’s 2020 white paper, The Association Between Drug Rebates and List Prices, found that increases in estimated rebates were associated with increases in list prices. Its estimated rebate measure included concessions throughout the distribution chain.

Pharmacy benefit manager contracts and Medicare Part D rebate reports add another reporting layer: Part D sponsors report manufacturer rebates and other remuneration to the Centers for Medicare & Medicaid Services.

What Evidence Is Needed to Prove Fraud?

The evidence connects the commercial transaction, the reported number, what the company knew and the government payment or rebate affected. Contracts explain what was promised. Transaction records show what changed hands. Calculations and certifications show what reached the government.

Contracts, Fees and Product Records

For a bundled discount, we connect the products in the agreement to the allocation used in Best Price. For a service fee, we examine the work described, the fair-market-value basis and whether a customer received part of the payment. For price appreciation, the inventory clause and the payment back to the manufacturer explain value that a sales invoice may miss.

Classification and base-date questions require a different comparison. The product’s approval and marketing history must be connected to the category and baseline the manufacturer used. The EpiPen and Acthar cases show why those fields deserve the same attention as the price itself.

Quarterly Reports, Assumptions and Certifications

The state reports drug utilization, and the manufacturer supplies the prices that determine the rebate on those units. Manufacturer-specific Average Manufacturer Price and Best Price information is confidential. An analyst who knows the calculation can explain a discrepancy that the public price lists cannot reveal.

A senior officer or direct delegate certifies the manufacturer’s price report. The supporting assumptions show how the company translated its commercial transactions into the certified numbers.

Timing, Corrections and the Payment Trail

Timing connects the concession to the correct report and payment period. Average Sales Price calculations use a rolling estimate when rebate and chargeback information arrives late.

A restatement can reveal which assumption changed and how far the correction reached. We examine the original calculation, the revised calculation and why the company changed it together.

The final connection is financial. In a Medicaid case, that means the rebate owed for the drugs used. In a Part B case, it means the reported Average Sales Price and the resulting reimbursement. In federal purchasing, it means the ceiling or contractual price and what the agency paid. Each comparison follows the particular program’s money.

What Triggers a Medicaid Fraud Investigation?

A whistleblower’s account of concealed discounts, misclassified drugs or inaccurate rebate calculations can bring a manufacturer’s reporting to the government’s attention. The Protonix allegations came from whistleblowers, and a competitor brought the EpiPen case.

A drug pricing fraud case connects a knowingly false report to money the government paid or should have received.

The Acthar allegations connect repeated warnings from the Centers for Medicare & Medicaid Services to the baseline the company continued using. The Protonix allegations connect hospital contract terms to discounts omitted from Medicaid reporting. The Eylea allegations connect payments through distributors to Average Sales Price and Medicare reimbursement. These are the connections we develop with you: the decision, the people who understood it and the money it changed.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Number Was Chosen

If you know which discounts, fees or product decisions disappeared between the commercial records and the government report, speak with our whistleblower experts about that discrepancy. We work with you to build your strongest drug pricing whistleblower case, showing who chose the reported number and how that choice changed government payments. We bring in pharmaceutical pricing whistleblower lawyers who know rebate and reimbursement disputes, and stay beside you through the case.